RT Journal Article
SR Electronic
T1 The prognostic value of lymph node involvement after neoadjuvant chemotherapy is different among breast cancer subtypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.05.20244582
DO 10.1101/2020.12.05.20244582
A1 Laot, Lucie
A1 Laas, Enora
A1 Girard, Noemie
A1 Dumas, Elise
A1 Daoud, Eric
A1 Grandal, Beatriz
A1 Pierga, Jean-Yves
A1 Coussy, Florence
A1 Kirova, Youlia
A1 Alam, Elsy el
A1 Bataillon, Guillaume
A1 Lae, Marick
A1 Llouquet, Florence
A1 Reyal, Fabien
A1 Hamy, Anne-Sophie
YR 2020
UL http://medrxiv.org/content/early/2020/12/07/2020.12.05.20244582.abstract
AB Introduction The three different breast cancer subtypes (Luminal, HER2-positive and triple negative (TNBCs) display different natural history and sensitivity to treatment, but little is known about whether residual axillary disease after neoadjuvant chemotherapy (NAC) carries a different prognostic value by BC subtype.Methods We retrospectively evaluated axillary involvement (0, 1 to 3 positive nodes, ≥ 4 positive nodes) on surgical specimens from a cohort of T1-T3NxM0 BC patients treated with NAC between 2002 and 2012. We analyzed the association between nodal involvement (ypN) binned into 3 classes (0; [1-3];4 or more), relapse-free survival (RFS) and overall survival (OS) among the global population, and according to BC subtypes.Results 1197 patients were included in the analysis (luminal (n = 526, 43.9%), TNBCs (n = 376, 31.4%), HER2-positive BCs (n = 295, 24.6%)). After a median follow-up of 110.5 months, ypN was significantly associated with RFS, but this effect was different by BC subtype (Pinteraction= 0.004), and this effect was nonlinear. In the luminal subgroup, RFS was impaired in patients with 4 or more nodes involved (HR=2.8; 95% CI [1.93;4.06], p<0.001) when compared with ypN0, while it was not in patients with 1 to 3 nodes (HR=1.24, 95% CI = [0,86;1.79]). In patients with TNBC, both 1-3N+ and ≥ 4 N+ classes were associated with a decreased RFS (HR=3.19, 95%CI= [2.05; 4.98] and HR=4.83, 95%CI= [3.06; 7.63], respectively versus ypN0, p< 0.001). Similar decreased prognosis were observed among patients with HER2-positive BC (1-3N+: HR=2.7, 95%CI= [1.64; 4.43] and ≥ 4 N+: HR=2.69, 95%CI= [1.24; 5.8] respectively, p=0.003).Conclusion The prognostic value of residual axillary disease should be considered differently in the 3 BC subtypes to accurately stratify patients with a high risk of recurrence after NAC who should be offered second line therapies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialInformed consent from patients was not required by French regulationsFunding StatementWe thank Roche France for financial support for the construction of the Institut Curie neoadjuvant database (NEOREP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent from patients was not required by French regulationsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available